Urticaria – Epidemiology – Mature Markets
DRG Epidemiology's coverage of urticaria comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of urticaria for each country, as well as annualized case counts projected for the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
DRG Epidemiology's urticaria forecast will answer the following questions:
Of all people diagnosed with urticaria, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of urticaria over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following urticaria patient populations:
Total 12-month prevalent cases of chronic spontaneous urticaria
Total 12-month prevalent cases of chronic inducible urticaria
Diagnosed 12-month prevalent cases of chronic spontaneous urticaria.
Diagnosed 12-month prevalent cases of chronic inducible urticaria.
Diagnosed 12-month prevalent cases of chronic urticaria.
Treatment subpopulation(s).
Note: Coverage may vary by country and region.
Table of contents
- Urticaria - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Diagnosed 12-month Prevalence of Chronic Urticaria per 100 Among People of All Ages in 2020 and 2040ttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed 12-month Prevalent Cases of Chronic Urticaria over the Next Twenty Yearsttttttttt
- Analysis of Diagnosed 12-month Prevalent Cases of Chronic Urticaria Across the Countries Under Study in 2020 by subtypettttttttt
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Lifetime Incident Cases
- Lifetime DALYs Gained
- Diagnosed chronic urticaria 12-month prevalent cases
- Total chronic spontaneous urticaria 12-month prevalence cases
- Total chronic inducible urticaria 12-month prevalent cases
- Diagnosed chronic spontaneous urticaria 12-month prevalent cases
- Diagnosed chronic inducible urticaria 12-month prevalent cases
- Diagnosed drug-treated prevalent cases
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Urticaria
- Studies Excluded from the Analysis of Urticaria
- Risk/Protective Factors
- Risk/Protective Factors for Urticaria
- Bibliography
- Glossary
- Literature Review
- Introduction
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.
